Table 1.

Previous studies of survival in ovarian cancer patients with BRCA mutations.

Author	Ovarian cancer cases	Ovarian cancer controls	Survival results
Rubin (US), 1996	n=53 BRCA1	n=53 (sporadic)	Overall Survival. 77 months vs. 29 months (p<0.001)
Aida (Japan), 1998	n=25 BRCA 1	n=29 (sporadic)	Overall Survival, 115 months vs 53 months 5-year survival, 78.6% vs 30.3% (p<0.05) Disease-free interval, 91 months vs 41 months (p<0.05)
Johannsson (Sweden), 1998	n=38 BRCA 1	n=97 (from registry)	No difference in long-term ovarian cancer survival.
Pharoah (UK), 1999	n=159, BRCA 1/2+n= 139, “Familial” (not tested)	n=552	No difference in survival b/w BRCA and controls.
Boyd (NY), 2000	n=88 Jewish BRCA+	n=101 Jewish BRCA-	BRCA cases had longer cumulative survival (p=0.004) Time to recurrence, 14 months vs. 7 months
Ben David (Israel), 2002 Chetrit (Israel), 2008	n=n=229 Jewish BRCA +	n=662 Jewish BRCA-	Overall Survival, 51.2 months vs. 33.1 months 3-year survival, 65.8% vs. 51.9% (p<0.001) Overall Survival, 53.7 months vs. 37.9 months (p=0.002) 5- year survival, 38.1% vs. 24.5% (p<0.001)
Cass (LA), 2003	n=34 Jewish BRCA+	n=37 Jewish BRCA-	Overall Survival, 91 months vs 54 months (p=0.046) 2-year survival, 100% vs. 83% (ns) 5-year survival, 65% vs. 48% (ns). Disease- free interval, 49 months vs. 19 months (ns)
Tan (UK), 2008	n=22 BRCA 1/2	n=44 “Non-hereditary”	Overall Survival, 100.8 months vs. 34.8 months (p<0.002)
Lacour/Lu (Current Study), 2009	n=95 BRCA 1/2 (“Non-Jewish”)	n=183 (sporadic)	Overall Survival, 83 months vs. 55 months (p<0.01) Progression- Free Survival, 25.4 months vs. 18.3 months (p<0.01)